[go: up one dir, main page]

CO2021011025A2 - Péptido con acción selectiva hacia receptores gip y glp-2 para el tratamiento contra trastornos óseos - Google Patents

Péptido con acción selectiva hacia receptores gip y glp-2 para el tratamiento contra trastornos óseos

Info

Publication number
CO2021011025A2
CO2021011025A2 CONC2021/0011025A CO2021011025A CO2021011025A2 CO 2021011025 A2 CO2021011025 A2 CO 2021011025A2 CO 2021011025 A CO2021011025 A CO 2021011025A CO 2021011025 A2 CO2021011025 A2 CO 2021011025A2
Authority
CO
Colombia
Prior art keywords
treatment
peptide
glp
receptors
bone disorders
Prior art date
Application number
CONC2021/0011025A
Other languages
English (en)
Inventor
Guillaume Mabilleau
Aleksandra Mieczkowska
Original Assignee
Univ Angers
Centre Hospitalier Univ Dangers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Angers, Centre Hospitalier Univ Dangers filed Critical Univ Angers
Publication of CO2021011025A2 publication Critical patent/CO2021011025A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/06—Flowable or injectable implant compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/24—Materials or treatment for tissue regeneration for joint reconstruction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)

Abstract

La presente invención se refiere a un péptido aislado que comprende la secuencia aminoacídica de consenso SEQ ID NO: 1: HGEGSFX7SDX10 SX12X13LDKLAARDFVNWLLQTK (SEQ ID NO: 1) en donde X7 es cualquier residuo aminoacídico, X10 es cualquier residuo aminoacídico, X12 es cualquier residuo aminoacídico y X13 es cualquier residuo aminoacídico, y su uso en el tratamiento contra trastornos óseos.
CONC2021/0011025A 2019-02-21 2021-08-20 Péptido con acción selectiva hacia receptores gip y glp-2 para el tratamiento contra trastornos óseos CO2021011025A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19305210.7A EP3699187A1 (en) 2019-02-21 2019-02-21 Peptide targeting gip and glp-2 receptors for treating bone disorders
PCT/EP2020/054604 WO2020169792A1 (en) 2019-02-21 2020-02-21 Peptide targeting gip and glp-2 receptors for treating bone disorders

Publications (1)

Publication Number Publication Date
CO2021011025A2 true CO2021011025A2 (es) 2021-11-19

Family

ID=65766924

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0011025A CO2021011025A2 (es) 2019-02-21 2021-08-20 Péptido con acción selectiva hacia receptores gip y glp-2 para el tratamiento contra trastornos óseos

Country Status (11)

Country Link
US (1) US20220112261A1 (es)
EP (2) EP3699187A1 (es)
JP (1) JP7507774B2 (es)
CN (1) CN113950482B (es)
AU (1) AU2020226823A1 (es)
BR (1) BR112021016571A2 (es)
CA (1) CA3129458A1 (es)
CO (1) CO2021011025A2 (es)
IL (1) IL285645A (es)
MX (1) MX2021010132A (es)
WO (1) WO2020169792A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023111278A2 (en) 2021-12-17 2023-06-22 Bainan Biotech Aps Peptides triple agonists of gip, glp-1 and glp-2
CN118843639A (zh) 2021-12-17 2024-10-25 白南生物技术有限公司 Gipr和glp2r的肽双重激动剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6294899A (en) 1998-10-07 2000-04-26 Medical College Of Georgia Research Institute, Inc. Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
PT1326630E (pt) 2000-09-18 2008-09-02 Sanos Bioscience As Utilização de péptidos glp-2
US20070135345A1 (en) * 2000-09-18 2007-06-14 Henriksen Dennis B Use of GLP-2 for the treatment or prevention, of bone-related disorders
AR080592A1 (es) * 2010-03-26 2012-04-18 Lilly Co Eli Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
KR102002783B1 (ko) * 2011-06-10 2019-07-24 베이징 한미 파마슈티컬 컴퍼니 리미티드 포도당 의존성 인슐리노트로핀 폴리펩타이드 유사물질, 이의 약학적 조성물 및 응용
WO2015067715A2 (en) * 2013-11-06 2015-05-14 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
JP2016169171A (ja) 2015-03-11 2016-09-23 国立大学法人 東京医科歯科大学 オステオプロテジェリン誘導体及びその用途
WO2018069442A1 (en) * 2016-10-12 2018-04-19 University Of Copenhagen Peptide dual agonists of gipr and glp2r
US20200261543A1 (en) * 2017-10-12 2020-08-20 University Of Copenhagen Combination therapy for treatment of bone disorders

Also Published As

Publication number Publication date
CN113950482B (zh) 2024-12-24
AU2020226823A1 (en) 2021-09-02
BR112021016571A2 (pt) 2021-11-03
CA3129458A1 (en) 2020-08-27
CN113950482A (zh) 2022-01-18
US20220112261A1 (en) 2022-04-14
JP2022522127A (ja) 2022-04-14
IL285645A (en) 2021-09-30
JP7507774B2 (ja) 2024-06-28
MX2021010132A (es) 2021-12-10
WO2020169792A1 (en) 2020-08-27
EP3927732A1 (en) 2021-12-29
EP3699187A1 (en) 2020-08-26

Similar Documents

Publication Publication Date Title
CO2021011025A2 (es) Péptido con acción selectiva hacia receptores gip y glp-2 para el tratamiento contra trastornos óseos
PE20180571A1 (es) Inhibidores peptidicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias
PE20141727A1 (es) Composiciones, usos y metodos para tratamiento de trastornos y enfermedades metabolicas
ECSP056236A (es) Agonistas del receptor de la melanocortina 4 (mc4) y sus usos
AR096162A1 (es) Péptidos terapéuticos
BR112015023071A2 (pt) conjugados de insulina-incretina
PH12018502465A1 (en) Mic-1 compounds and use thereof
UA103526C2 (ru) Воспроизведенный сурфактант, который содержит аналоги белков естественных сурфактантов sp-b и sp-c
PH12019550241A1 (en) Mic-1 compounds and uses thereof
CL2017002729A1 (es) Proteína de unión a rgma y su uso
UY33222A (es) Secuencias de aminoácidos dirigidas contra el receptor de superficie celular 2 de TRAIL, compuestos, construcciones y variantes efectivas
PE20211417A1 (es) Analogos novedosos de glp-1
PE20211466A1 (es) Analogos de proteina tirosina-tirosina y metodos de uso de esta
CL2021003266A1 (es) Anticuerpos de receptor de péptido natriurético 1 y métodos de uso
NZ743488A (en) Controlled-release cnp agonists with low initial npr-b activity
CO6400235A2 (es) Tensiactivos reconstituidos que tienen propiedades mejoradas
MX366906B (es) Purificacion de iduronato-2-sulfatasa.
ES2538486T3 (es) Preparación de péptidos antigénicos contra el cáncer
BR112017025000A2 (pt) tratamento de hipoglicemia pós-bariátrica com exendina (9-39)
MY193807A (en) T-cell receptor and uses thereof
NZ736652A (en) Short synthetic peptide for treating diseases and/or conditions related to angiogenesis
EA201792640A1 (ru) Устойчивые к действию протеазы липидированные аналоги glp-1
PE20171320A1 (es) Analogos de calcitonina para tratar enfermedades y trastornos
PE20121553A1 (es) Uso de una fuente de l3 y/o l5 como vacuna o como diagnostico para una efermedad parasitaria
PH12021551243A1 (en) Oxyntomodulin peptide analog formulations